(Total Views: 377)
Posted On: 03/09/2017 4:08:24 PM
Post# of 23059
$CDXS
a leading protein engineering company, announces financial results for the three and 12 months ended December 31, 2016 , and provides a business update.
“Our solid fourth quarter performance completes a year of consistently strong
results for Codexis. Full year 2016 revenues closed at $48.8 million , a growth
of 17% versus 2015 and at the top end of our annual guidance,” said Codexis
President and CEO John Nicols . “This is our third consecutive year to meet or
exceed our annual guidance targets and to deliver double-digit revenue
growth. In addition to tight execution on the early completion of CodeEvolver®
platform technology transfers for both GSK and Merck in 2016, we are most proud
of stepping up our product sales by 35% in 2016.
a leading protein engineering company, announces financial results for the three and 12 months ended December 31, 2016 , and provides a business update.
“Our solid fourth quarter performance completes a year of consistently strong
results for Codexis. Full year 2016 revenues closed at $48.8 million , a growth
of 17% versus 2015 and at the top end of our annual guidance,” said Codexis
President and CEO John Nicols . “This is our third consecutive year to meet or
exceed our annual guidance targets and to deliver double-digit revenue
growth. In addition to tight execution on the early completion of CodeEvolver®
platform technology transfers for both GSK and Merck in 2016, we are most proud
of stepping up our product sales by 35% in 2016.
(1)
(0)
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.
